TRIFECTA SIGNALS

KYNB stock report

Trifecta Signals · Data as of Nov 2, 2026

Latest close $4.46 · Mon, Nov 2, 2026 · Market cap now $21M

Free edition. This report shows the public record for KYNB. The full signal timeline, group mix, and marked chart are member content — see the box at the end.

Kyntra Bio, Inc. (KYNB)


Mid cap · Healthcare — Drug Manufacturers - Specialty & Generic

CONFIRMED SIGNALS ON RECORD	MEDIAN RETURN SINCE EARLY SIGNAL (REFERENCE ONLY)	REACHED +10% WITHIN 90 DAYS (DECIDED SIGNALS)	BEAT THE S&P 500 SINCE CONFIRMATION
1	-98.6%	0 of 1	0 of 1

Headline statistics: confirmed signals only, measured from the confirmation price.

Since March 2022, Kyntra has had four Early signals, one confirmed. Its one decided signal did not reach +10% within 90 days, and it did not finish ahead of the S&P 500 since confirmation. Three Early signals never confirmed and count in no statistic.

Weekly closes (adjusted). Signal marks are member content and are not drawn on the free-edition chart.



🔒 Members get the full KYNB record

- The full signal timeline — every Early signal with its exact dates, group tag, and caution flags
- The group mix — how this stock's confirmed signals split across the groups
- The price chart with every Early and Confirmed signal marked on it
- Entry prices and per-signal grading in the member screener

See membership options at **trifectasignals.com**

Trifecta Signals flags oversold stocks as they turn bullish — three oversold signals, one Early Signal — and tracks every signal in the open. Statistics are confirmed-only. This report is the public record for KYNB; it is not investment advice.